Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.

Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, Baker GS, Breitz HB.

J Clin Oncol. 2009 Apr 20;27(12):2046-51. doi: 10.1200/JCO.2008.19.3235. Epub 2009 Mar 16.

PMID:
19289620
2.

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR.

J Nucl Med. 2008 Nov;49(11):1884-99. doi: 10.2967/jnumed.108.053173. Epub 2008 Oct 16. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

3.

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.

Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Champlin R, Giralt S.

Biol Blood Marrow Transplant. 2007 May;13(5):543-9. Epub 2007 Feb 26.

4.

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

Breitz HB, Wendt RE 3rd, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.

J Nucl Med. 2006 Mar;47(3):534-42.

5.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
6.

Blood-based red marrow dosimetry: where's the beef?

Siegel JA, Sparks RB, Sharkey RM, Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Meredith RF, Sgouros G, Stabin MG.

J Nucl Med. 2005 Aug;46(8):1404-6; author reply 1405-6. No abstract available.

7.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.

J Nucl Med. 2005 Apr;46(4):642-51.

8.

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Shen S, Meredith R, Duan J, Forero A, Breitz H, Khazaeli MB, Brezovich I, LoBuglio A.

Cancer Biother Radiopharm. 2005 Feb;20(1):110-8.

PMID:
15778590
9.

Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G; American Association of Physicists in Medicine.

J Nucl Med. 2004 Oct;45(10):1725-33.

10.

Clinical aspects of radiation nephropathy.

Breitz H.

Cancer Biother Radiopharm. 2004 Jun;19(3):359-62. Review.

PMID:
15285883
11.

Dosimetry model for radioactivity localized to intestinal mucosa.

Fisher D, Rajon D, Breitz H, Goris M, Bolch W, Knox S.

Cancer Biother Radiopharm. 2004 Jun;19(3):293-307.

PMID:
15285876
12.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.

Blood. 2004 Jul 1;104(1):227-36. Epub 2004 Mar 2.

PMID:
14996706
13.

Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.

Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B.

Cancer Biother Radiopharm. 2003 Apr;18(2):225-30.

PMID:
12804048
14.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.

Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R.

Blood. 2003 Oct 1;102(7):2684-91. Epub 2003 May 1.

PMID:
12730103
15.

Dosimetry in a myeloablative setting.

Breitz H.

Cancer Biother Radiopharm. 2002 Feb;17(1):119-28. Review.

PMID:
11915169
16.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

Weiden PL, Breitz HB.

Crit Rev Oncol Hematol. 2001 Oct;40(1):37-51.

PMID:
11578915
17.

Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method.

Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB.

J Nucl Med. 2001 Mar;42(3):492-8.

18.

How far have we come with solid (nonhematologic) tumor radioimmunotherapy?

Breitz HB.

J Nucl Med. 2000 Dec;41(12):2011-4. No abstract available.

19.

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.

Cancer Biother Radiopharm. 1999 Oct;14(5):381-95.

PMID:
10850323
20.
21.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.

Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.

PMID:
10740649
22.

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.

Clin Cancer Res. 2000 Feb;6(2):406-14.

23.

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM.

J Nucl Med. 2000 Jan;41(1):131-40.

24.
25.

Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy.

Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL.

Clin Nucl Med. 1997 Sep;22(9):615-20.

PMID:
9298295
26.

The 10th International Conference on Monoclonal Antibody Immunoconjugates for Cancer: Radiodosimetry and Radiopharmaceuticals for Therapy.

Breitz H, Mills G, Siegel J, Stabin M, Wessels BW.

Cancer Biother Radiopharm. 1996 Feb;11(1):25-42. No abstract available.

PMID:
10851518
27.
28.

Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.

Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.

J Nucl Med. 1995 May;36(5):754-61.

29.

Human anti-mouse antibody suppression with cyclosporin A.

Weiden PL, Wolf SB, Breitz HB, Appelbaum JW, Seiler CA, Mallett R, Bjorn MJ, Su FM, Fer MF, Salk D.

Cancer. 1994 Feb 1;73(3 Suppl):1093-7.

PMID:
8306252
30.

Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.

Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D.

J Nucl Med. 1993 Dec;34(12):2111-9.

31.

A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.

Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P.

Obstet Gynecol. 1993 Oct;82(4 Pt 1):586-93.

PMID:
8377986
32.

Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.

Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG.

J Nucl Med. 1993 Jun;34(6):908-17.

33.

Imaging lung cancer with radiolabeled antibodies.

Breitz HB, Sullivan K, Nelp WB.

Semin Nucl Med. 1993 Apr;23(2):127-32. Review.

PMID:
8390098
34.

Dosimetry of solid tumors.

Meredith RF, Johnson TK, Plott G, Macey DJ, Vessella RL, Wilson LA, Breitz HB, Williams LE.

Med Phys. 1993 Mar-Apr;20(2 Pt 2):583-92. Review.

PMID:
8492767
35.

Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.

Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, et al.

J Nucl Med. 1992 Jun;33(6):1099-109.

36.

Localization of inflammation with 111In IgG and 99Tcm albumin colloid labelled leukocytes in a rabbit model.

Breitz HB, Modell HI, Graham MM.

Nucl Med Commun. 1990 Nov;11(11):737-45.

PMID:
2277689
37.

Pleuroperitoneal communication associated with malignant ascites. A potential cause for new pleural effusion suggestive of pulmonary embolism.

Jacobson AF, Cerqueira MD, Breitz HB, Whitley MA, Higano CS.

Clin Nucl Med. 1990 May;15(5):317-20.

PMID:
2340673
38.

Cardiac calcification causing arrhythmia detected by technetium-99m MDP and SPECT.

Breitz HB, Sirotta PS, Graham MM.

Clin Nucl Med. 1988 Mar;13(3):153-4.

PMID:
3383518
39.

Progressive pulmonary calcification complicating successful renal transplantation.

Breitz HB, Sirotta PS, Nelp WB, Ott S, Figley MM.

Am Rev Respir Dis. 1987 Dec;136(6):1480-2.

PMID:
3318601

Supplemental Content

Loading ...
Support Center